To date, only three studies have addressed the immunization paradigm using either recombinant fibrils (Sankaranarayanan et al., 2015) or human phosphorylated tau isolated from Alzheimer’s disease brain tissues (Dai et al., 2018; Vandermeeren et al., 2018). The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.